Thermo Fisher Scientific Inc.

TMO Healthcare Diagnostics & Research

Thermo Fisher Scientific Inc.’s revenue for fiscal 2025 (year ended December 2025) was $44.6 billion, up 3.91% from fiscal 2024. In the quarter to June 2026, revenue grew 10.5%, EPS grew 9.35%, free cash flow grew 51.8% and total debt rose 18.7%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years.

690.00 6.49 −0.93%
Market cap
$257.5B
P/E
37.1×
Fwd P/E
23.7×
Dividend yield
0.27%
F-score
5/9
Altman Z
3.84
Beneish M
−2.46
Dividend safety
88/100
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
P/E ratio
32.61 31.38 35.06 31.15 34.03 28.95 35.16 30.66 34.16 28.01
Piotroski F-Score
5 7 5 5 5 8 8 7 4 7
P/S ratio
4.90 4.63 4.90 4.83 6.70 5.73 5.09 3.69 3.64 3.11
Altman Z-Score
3.84 4.06 3.83 3.89 4.27 4.82 4.06 3.10 2.42 2.43
Altman Z″-Score (non-manufacturers)
4.01 3.97 3.68 3.41 3.17 4.24 3.49 3.07 2.39 2.58
P/FCF ratio
34.47 27.13 29.95 31.27 38.61 27.03 31.83 23.46 21.75 19.98
Beneish M-Score
(2.46) (2.58) (2.53) (2.50) (2.18) (2.44) (2.51) (2.52) (2.50) (2.45)
P/Operating CF
63.19 60.40 56.42 62.19 107.00 55.24 67.93 49.95 40.85 47.08
Dividend Safety Score
88 — — — — — — — — —
P/B ratio
4.09 4.01 4.50 4.92 6.43 5.34 4.38 3.26 3.00 2.63
Price to Tangible BV
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EV/Sales
5.48 5.18 5.44 5.28 7.42 6.00 5.66 4.33 4.48 3.90
EV/EBITDA
23.20 21.27 22.72 20.15 23.04 19.10 21.05 17.45 18.78 16.92
EV/Operating CF
31.24 25.64 27.75 25.92 31.22 23.31 29.08 23.24 23.41 21.90
EV/FCF
38.54 30.34 33.26 34.21 42.70 28.32 35.42 27.53 26.76 25.12
Quick Ratio
1.25 1.03 1.16 0.98 0.93 1.56 1.09 1.02 0.74 0.87
Current Ratio
1.89 1.66 1.75 1.48 1.50 2.13 1.92 1.73 1.34 1.44
Net Debt/EBITDA
2.45 2.25 2.26 1.73 2.21 0.87 2.14 2.58 3.51 3.46
Debt/Assets
32.49% 29.86% 31.71% 29.76% 33.99% 27.67% 29.25% 31.51% 33.30% 33.48%
Debt/Equity
0.67 0.59 0.67 0.66 0.79 0.55 0.58 0.64 0.74 0.71
Asset Turnover
0.43 0.44 0.44 0.47 0.48 0.51 0.45 0.43 0.41 0.42
Operating CF/Net income
1.17 1.37 1.40 1.32 1.21 1.30 1.35 1.55 1.80 1.61
Capex/Depreciation
(0.53) (0.43) (0.41) (0.66) (0.97) (0.63) (0.39) (0.31) (0.25) (0.24)
Interest Coverage
5.46 5.28 4.99 11.56 18.71 14.09 6.80 5.67 5.00 51.21
ROE
13.02% 13.16% 13.21% 16.37% 20.50% 19.86% 12.91% 11.09% 9.48% 9.43%
ROA
6.46% 6.46% 6.12% 7.23% 9.41% 10.01% 6.45% 5.20% 4.34% 4.66%
ROIC
6.12% 6.28% 6.13% 8.14% 9.12% 11.25% 6.47% 5.47% 4.31% 4.25%
Return on Tangible Assets
27.84% 34.98% 29.94% 39.72% 51.47% 36.29% 35.39% 33.99% 34.66% 42.72%
Average Days of Receivables
72.91 69.72 70.02 65.95 74.25 65.04 62.15 61.98 67.69 68.45
Research and Development Expense of Revenue
3.14% 3.24% 3.12% 3.28% 3.59% 3.67% 3.93% 3.97% 4.24% 4.13%
Selling, General and Administrative Expense of Revenue
19.60% 20.04% 19.71% 20.02% 20.42% 21.51% 24.05% 24.87% 26.31% 27.20%
Intangible Assets out of Total Assets
0.59 0.63 0.61 0.60 0.65 0.56 0.68 0.72 0.74 0.77
Share Based Compensation of Revenue
0.70% 0.70% 0.65% 0.68% 0.59% 0.61% 0.71% 0.74% 0.76% 0.73%
Graham Net Nets
(0.13) (0.13) (0.13) (0.13) (0.13) (0.07) (0.13) (0.20) (0.29) (0.31)
Graham Number
238.01 219.98 205.60 211.86 213.90 177.64 124.19 106.17 90.44 79.34
Earnings Yield
3.07% 3.19% 2.85% 3.21% 2.94% 3.45% 2.84% 3.26% 2.93% 3.57%
Free Cash Flow Yield
2.90% 3.69% 3.34% 3.20% 2.59% 3.70% 3.14% 4.26% 4.60% 5.00%
Revenue per Share
118.19 112.25 111.03 114.58 99.52 81.36 63.86 60.59 52.96 46.26
Operating CF per Share
20.74 22.69 21.78 23.35 23.63 20.93 12.43 11.30 10.14 8.25
Capex per Share
(3.93) (3.52) (3.61) (5.66) (6.35) (3.70) (2.22) (1.76) (1.27) (1.06)
Free Cash Flow per Share
16.81 19.17 18.17 17.69 17.28 17.23 10.21 9.54 8.87 7.19
Cash per Share
26.80 14.58 20.93 21.74 11.36 26.07 6.00 5.23 3.38 1.99
Shareholders Equity per Share
141.68 129.71 121.05 112.33 103.69 87.16 74.19 68.62 64.34 54.53
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
141.68 129.71 121.05 112.33 103.69 87.16 74.19 68.62 64.34 54.53
Free Cash Flow
6,337.00 7,324.00 7,014.00 6,935.00 6,809.00 6,823.00 4,083.00 3,835.00 3,504.00 2,840.00
Working Capital
13,518.00 8,805.00 10,577.00 8,219.00 6,677.00 11,653.00 5,696.00 4,478.00 2,373.00 2,155.00
Capital Expenditures
(1,481.00) (1,343.00) (1,392.00) (2,219.00) (2,503.00) (1,466.00) (890.00) (708.00) (501.00) (418.00)
Net Current Asset Value
(28,221.00) (25,633.00) (27,413.00) (27,893.00) (34,155.00) (12,578.00) (16,813.00) (18,021.00) (21,835.00) (17,347.00)
EV/EBIT
31.52 30.28 34.01 28.27 28.99 24.79 31.48 27.91 31.68 29.02
Capex to Sales
0.03 0.03 0.03 0.05 0.06 0.05 0.03 0.03 0.02 0.02
Price to Operating Income
28.20 27.08 30.62 25.84 26.22 23.67 28.29 23.78 25.75 23.09
Other line items
Depreciation/Fixed assets
0.26 0.33 0.36 0.36 0.31 0.39 0.48 0.54 0.50 0.68
Cash ROIC
6.38% 8.70% 8.15% 8.51% 8.77% 10.67% 8.31% 8.09% 7.68% 7.53%
Accounts Receivable Turnover
5.21 5.23 5.25 5.58 5.72 6.39 6.02 6.08 5.73 5.90
Accounts Payable Turnover
7.85 8.46 8.24 8.30 7.76 7.92 8.04 8.87 9.75 11.33
Inventory Turnover
5.06 5.00 4.80 4.86 4.31 4.38 4.46 4.52 4.43 4.71
Average Days of Payables
50.23 44.64 40.70 47.57 53.46 48.96 49.30 43.66 45.44 34.13
Days of Inventory on Hand
75.24 72.17 72.10 79.26 94.19 90.70 86.54 81.24 94.54 81.57
Average Receivables
8,545.50 8,206.00 8,168.00 8,046.00 6,859.00 5,045.00 4,242.50 4,007.50 3,653.00 3,095.00
Average Payables
3,350.50 2,975.50 3,126.50 3,124.00 2,521.00 2,047.50 1,767.50 1,521.50 1,177.00 874.10
Average Inventory
5,201.50 5,033.00 5,361.00 5,342.50 4,540.00 3,699.50 3,187.50 2,988.00 2,592.00 2,102.35
Average Assets
103,832.00 98,023.50 97,940.00 96,138.50 82,087.50 63,716.50 57,306.50 56,450.50 51,288.50 43,371.15
Average Common Equity
51,483.00 48,138.00 45,378.00 42,443.50 37,686.00 32,096.00 28,630.50 26,499.50 23,476.50 21,445.10

Fold the line items

Columns are period end dates